TAP vs. ESP Block for Gynecological Post Operative Pain

Sponsor

Universitas Padjadjaran (Other)

Overall Status

Completed

CT.gov ID

NCT06044779

Collaborator

(none)

Enrollment

Location

Arms

2.9

Actual Duration (Months)

13.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this double blind randomized controlled trial is to compare transversus abdominis plane block and erector spinae plane block in gynecological surgery patients. The main questions it aims to answer are:

What are the numerical post-operative pain scores in these two groups?
Is there any significant difference in the numerical post-operative pain scores between subjects who underwent TAP block and subjects who underwent ESP block?
What are the differences in the time needed for additional morphine in these two groups?
Is there any significant differences in the time needed for additional morphine between subjects who underwent TAP block and subjects who underwent ESP block?

Condition or Disease	Intervention/Treatment	Phase
Nerve Block Pain, Postoperative	Procedure: Transversus Abdominis Plane Block using 0.25% Bupivacaine Procedure: Erector Spinae Plane Block using 0.25% Bupivacaine	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

40 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Care Provider)

Primary Purpose:

Other

Official Title:

Transversus Abdominis Plane (TAP) Block and Erector Spinae Plane (ESP) Block Comparison on Postoperative Pain and the Need for Morphine in Gynecological Surgery Patients Who Underwent Median Incision in Hasan Sadikin General Hospital

Actual Study Start Date :

Dec 27, 2022

Actual Primary Completion Date :

Mar 26, 2023

Actual Study Completion Date :

Mar 26, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Transversus Abdominis Plane (TAP) Anesthestic Block Ultrasound-guided TAP block is done using 20 mL of 0.25% Bupivacaine administered at the lateral abdominal wall between the costal margin and the iliac crest	Procedure: Transversus Abdominis Plane Block using 0.25% Bupivacaine TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
Active Comparator: Erector Spinae Plane (ESP) Anesthetic Block Ultrasound-guided ESP block is done using 20 mL of 0.25% Bupivacaine administered at the tip of the transverse process at the T9 level	Procedure: Erector Spinae Plane Block using 0.25% Bupivacaine Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.

Arm

Intervention/Treatment

Active Comparator: Transversus Abdominis Plane (TAP) Anesthestic Block

Ultrasound-guided TAP block is done using 20 mL of 0.25% Bupivacaine administered at the lateral abdominal wall between the costal margin and the iliac crest

Procedure: Transversus Abdominis Plane Block using 0.25% Bupivacaine

TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.

Active Comparator: Erector Spinae Plane (ESP) Anesthetic Block

Ultrasound-guided ESP block is done using 20 mL of 0.25% Bupivacaine administered at the tip of the transverse process at the T9 level

Procedure: Erector Spinae Plane Block using 0.25% Bupivacaine

Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.

Outcome Measures

Primary Outcome Measures

Postoperative Numerical Rating Scale [24 hours post operative]
The degree of pain assessment is classified based on the Numeric Rating Scale pain assessment scale) with the lowest scale being no pain (value 0), up to the heaviest pain scale (value 10) when still, namely when the patient does not make any movement and moves, namely when mobilization is carried out on the left side and right tilt

Secondary Outcome Measures

Total postoperative morphine requirements [24 hours post operative]
The total amount of morphine required by study subjects over 24 hours to reduce postoperative pain
Time of first need for analgesic rescue [24 hours post operative]
The time required by study subjects to press the PCA to obtain analgesics was first calculated from the time it was installed in the recovery room

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects with gynecological surgery techniques with a median incision include: hysterectomy, myomectomy, salpingectomy, ovarectomy and ovarian cystectomy.
Subjects with physical status based on the American Society of Anesthesiologists (ASA) in categories I-II
Subjects who are willing to sign informed consent form.

Exclusion Criteria:

The patient has a history of allergies to local anesthetic drugs used for TAP blockade or ESP blockade and is allergic to morphine.
Patients who have skin infections at the injection site.
Patients with a history of chronic pain, namely a history of pain for more than 1 month obtained from history taking.
Patients with a history of chronic pain treatment obtained from history taking.
Patients with impaired kidney function (Ureum >39 mg/dL; Creatinine >1.3 mg/dL) and liver (SGOT >37 U/L; SGPT >59 U/L), myopathy, coagulopathy obtained from the results of supporting examinations, heart rhythm disorders obtained from the results of an EKG examination and neurological disorders in the form of hypesthesia or paraesthesia obtained from the results of a physical examination in the form of a sensory examination.
The patient is pregnant as determined by history taking.
Patients who are illiterate as obtained from history taking.
The patient was uncooperative during examination.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hasan Sadikin General Hospital	Bandung	West Java	Indonesia

Sponsors and Collaborators

Universitas Padjadjaran

Investigators

Study Director: Doddy M Tavianto, MD, Faculty of Medicine Universitas Padjadjaran Bandung
Study Director: Osmond M Pison, MD, Faculty of Medicine Universitas Padjadjaran Bandung
Principal Investigator: Azka P Rakhimulllah, MD, Faculty of Medicine Universitas Padjadjaran Bandung